

### Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

### Cellectar Biosciences to Present at Two Upcoming Investor Conferences

Sep 10 2020, 8:00 AM EDT

### Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

Sep 9 2020, 8:00 AM EDT

### Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA

Aug 17 2020, 10:01 AM EDT

### Stock Overview

Symbol	CLRB
Exchange	Nasdaq
Market Cap	32.75m
Last Price	\$1.23
52-Week	\$1.01 - \$3.33

10/20/2020 04:00 PM EDT

### Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820
<a href="mailto:monique@lifesciadvisors.com">monique@lifesciadvisors.com</a>

### Management Team

#### James Caruso

President, CEO and Director

#### Dov Elefant

Vice President and Chief Financial Officer

#### Dr. John Friend

Chief Medical Officer

#### Jarrod Longcor

Chief Business Officer

### Cellectar Biosciences, Inc.

100 Campus Drive, Suite 207  
Florham Park, NJ 07932

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.